Health Catalyst price target lowered to $1.75 from $2 at Stephens

Stephens lowered the firm’s price target on Health Catalyst (HCAT) to $1.75 from $2 and keeps an Equal Weight rating on the shares. The combination of better-than-expected Q1 and below-consensus FY26 guidance yield a lower-than-anticipated exit rate that will drive down revenue estimates for FY26 and FY27, the analyst tells investors.